Cargando…

Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes

Detalles Bibliográficos
Autores principales:	Ndrepepa, Gjin, Holdenrieder, Stefan, Bernlochner, Isabell, Kastrati, Adnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242954/ https://www.ncbi.nlm.nih.gov/pubmed/34850261 http://dx.doi.org/10.1007/s00392-021-01976-y

Ejemplares similares

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
por: Koch, Tobias, et al.
Publicado: (2023)

Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial
por: Gewalt, Senta, et al.
Publicado: (2022)

Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
por: Ndrepepa, Gjin, et al.
Publicado: (2021)

Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes ‐ A Post‐hoc Analysis of the ISAR‐REACT 5 Trial
por: Lahu, Shqipdona, et al.
Publicado: (2022)

Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy
por: Ndrepepa, Gjin, et al.
Publicado: (2023)

Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
por: Behnes, Michael, et al.
Publicado: (2022)

Long‐Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST‐Segment–Elevation Myocardial Infarction
por: Cassese, Salvatore, et al.
Publicado: (2020)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
por: Dai, Lulu, et al.
Publicado: (2022)

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis
por: Wen, Mingxiang, et al.
Publicado: (2020)

High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
por: Mayer, Katharina, et al.
Publicado: (2023)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

Antiplatelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel
por: KIRKBY, N S, et al.
Publicado: (2011)

Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study
por: Alexopoulos, Dimitrios, et al.
Publicado: (2015)

Epicardial adipose tissue: An anatomic component of obesity & metabolic syndrome in close proximity to myocardium & coronary arteries
por: Ndrepepa, Gjin
Publicado: (2020)

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
por: Yildirim, Mustafa, et al.
Publicado: (2023)

Association of De Ritis Ratio with Prognosis in Patients with Coronary Artery Disease and Aminotransferase Activity within and outside the Healthy Values of Reference Range
por: Ndrepepa, Gjin, et al.
Publicado: (2023)

Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease
por: Ndrepepa, Gjin, et al.
Publicado: (2014)

Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction
por: Sager, Hendrik B., et al.
Publicado: (2019)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

“Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States
por: Larmore, Cynthia, et al.
Publicado: (2015)

De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early?
por: Masiero, Giulia, et al.
Publicado: (2020)

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017
por: Rezaei, Safoura Sheikh, et al.
Publicado: (2020)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

Commentary: Ticagrelor monotherapy—Not for CABG?
por: Sandner, Sigrid, et al.
Publicado: (2022)

Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial
por: Schnorbus, Boris, et al.
Publicado: (2021)

Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes
por: Husted, Steen, et al.
Publicado: (2016)

Prasugrel versus ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: A critical appraisal of randomized controlled trials
por: Almas, Talal, et al.
Publicado: (2022)

Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients
por: Gager, Gloria M., et al.
Publicado: (2020)

Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry
por: Khayata, Mohamed, et al.
Publicado: (2017)

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
por: Kumar, Arun, et al.
Publicado: (2022)

Tolvaptan in the very elderly with acute decompensated heart failure-a therapeutic option worth of consideration
por: Ndrepepa, Gjin
Publicado: (2017)

Atherosclerosis & ischaemic heart disease: Here to stay or gone tomorrow
por: Ndrepepa, Gjin
Publicado: (2017)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
por: Kim, Yuri, et al.
Publicado: (2023)

Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study
por: Winter, Max-Paul, et al.
Publicado: (2019)

Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Treating patients suffering from acute coronary syndrome with prasugrel, the Rotterdam experience
por: de Winter, R. J.
Publicado: (2018)

Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study
por: Schnorbus, Boris, et al.
Publicado: (2014)

Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
por: Wiebe, Jens, et al.
Publicado: (2021)

Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta‐analysis
por: Chen, Wenwen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pfbmadi64rrr3v7e4lr8m40rj5